Atrium Therapeutics, Inc. (RNA)
NASDAQ:RNA
Want to see RNA full AI Analyst Report?
Top Page
Atrium Therapeutics, Inc.
(NASDAQ:RNA)
Select Model
Select Model
Rating:54Neutral
Price Target:
$74.00
▲(413.53% Upside)
Action:Reiterated
Date:02/28/26
The score is primarily held back by weak financial performance (rapidly widening losses and accelerating cash burn) and a major corporate event (merger completion with planned Nasdaq delisting). Technicals are moderately supportive, but valuation is not compelling given ongoing unprofitability and no dividend.
Positive Factors
Low-leverage balance sheet
Avidity’s very low debt-to-equity (~0.03) and sizable asset/equity base (~$2.0B assets, ~$1.69B equity) provide durable financial flexibility to fund clinical programs and absorb R&D spend over the next 2–6 months, lowering near-term refinancing risk while programs advance.
Negative Factors
Accelerating cash burn
Cash consumption more than doubled year-over-year, indicating materially higher financing needs. Persistent, large negative operating cash flow increases dilution risk, constrains discretionary R&D choices and elevates execution risk if capital access tightens over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low-leverage balance sheet
Avidity’s very low debt-to-equity (~0.03) and sizable asset/equity base (~$2.0B assets, ~$1.69B equity) provide durable financial flexibility to fund clinical programs and absorb R&D spend over the next 2–6 months, lowering near-term refinancing risk while programs advance.
Read all positive factors
Atrium Therapeutics, Inc. (RNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$222.37M
Dividend YieldN/A
Average Volume (3M)2.09M
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees511
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,105,642
10 Day Avg. Volume2,820,857
30 Day Avg. Volume2,094,181
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)5.88
Price to Sales (P/S)529.62
P/FCF Ratio-14.96
Enterprise Value/Market Cap8.95
Enterprise Value/Revenue106.14
Enterprise Value/Gross Profit-16.47
Enterprise Value/Ebitda-2.82
Forecast
1Y Price Target
$25.00Price Target Upside73.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Atrium Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates includ...
How the Company Makes Money
Avidity Biosciences generates revenue through a combination of research and development collaborations, partnerships, and potential product sales. The company often enters into strategic collaborations with larger pharmaceutical companies, which m...
Atrium Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 18.62M | 10.90M | 9.56M | 9.22M | 9.33M |
| Gross Profit | 18.62M | 10.90M | 7.46M | 7.84M | -91.86M |
| EBITDA | -76.49M | -376.16M | -233.50M | -177.53M | -117.41M |
| Net Income | -76.68M | -322.30M | -212.22M | -174.00M | -118.01M |
Balance Sheet | |||||
| Total Assets | 278.35M | 1.56B | 628.55M | 638.80M | 427.58M |
| Cash, Cash Equivalents and Short-Term Investments | 270.00M | 1.50B | 595.35M | 610.73M | 405.54M |
| Total Debt | 3.67M | 6.80M | 9.85M | 10.69M | 11.73M |
| Total Liabilities | 71.07M | 138.94M | 127.79M | 60.73M | 46.15M |
| Stockholders Equity | 207.29M | 1.42B | 500.76M | 578.08M | 381.43M |
Cash Flow | |||||
| Free Cash Flow | -42.57M | -307.94M | -123.29M | -139.09M | -98.55M |
| Operating Cash Flow | -41.13M | -300.87M | -119.06M | -136.27M | -94.81M |
| Investing Cash Flow | -1.45M | -854.20M | -130.07M | -189.96M | -82.52M |
| Financing Cash Flow | 42.57M | 1.19B | 93.86M | 346.17M | 176.32M |
Atrium Therapeutics, Inc. Technical Analysis
Negative
14.41
Price Trends
Market Momentum
0.14
Positive
58.43
Neutral
29.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNA, the sentiment is Negative. The current price of 14.41 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 58.43 is Neutral, neither overbought nor oversold. The STOCH value of 29.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNA.
Atrium Therapeutics, Inc. Risk Analysis
Atrium Therapeutics, Inc. disclosed 92 risk factors in its most recent earnings report. Atrium Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atrium Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $6.84B | -13.24 | -68.16% | ― | ― | -1.22% | |
56 Neutral | $6.13B | -32.61 | 99.84% | ― | -53.34% | -130.87% | |
54 Neutral | $222.37M | -3.35 | -29.67% | ― | ― | ― | |
52 Neutral | $6.05B | -29.47 | -203.25% | ― | 58.67% | -11.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $5.42B | -9.16 | -30.88% | ― | -89.11% | -37.55% |
* Healthcare Sector Average
RNA
Atrium Therapeutics, Inc.
12.68
-2.07
-14.03%
PTCT
PTC Therapeutics
73.80
24.97
51.14%
CRSP
Crispr Therapeutics AG
54.19
17.24
46.66%
RYTM
Rhythm Pharmaceuticals
87.87
24.21
38.03%
IMVT
Immunovant
32.86
17.45
113.24%
Atrium Therapeutics, Inc. Corporate Events
Executive/Board ChangesDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
Avidity Biosciences Completes Merger and Plans Nasdaq Delisting
Negative
Feb 27, 2026
Following the closing of a previously agreed merger, Avidity Biosciences terminated its equity incentive plans, employee stock purchase plan and an August 9, 2024 sales agreement with TD Securities, and on February 27, 2026 notified Nasdaq that it...
M&A TransactionsShareholder Meetings
Avidity Shareholders Approve Novartis Merger and Spin-Off
Positive
Feb 26, 2026
At a special meeting held virtually on February 26, 2026, Avidity Biosciences stockholders approved the Agreement and Plan of Merger with Novartis AG and the Separation and Distribution Agreement related to the spin-off of assets into Atrium Thera...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsShareholder Meetings
Avidity Biosciences Advances Toward Novartis Merger Completion
Positive
Feb 23, 2026
On February 23, 2026, Avidity Biosciences, Inc. announced that it would open its special meeting of stockholders scheduled for that day and immediately adjourn it, reconvening on February 26, 2026 via the same virtual link. The adjournment is inte...
Business Operations and StrategyM&A Transactions
Avidity Plans Spin-Off Amid Novartis Acquisition Agreement
Neutral
Feb 3, 2026
On February 2, 2026, Avidity Biosciences announced that its board has set February 12, 2026, as the expected record date for a pro rata spin-off of Atrium Therapeutics (SpinCo), distributing one share of SpinCo common stock for every ten Avidity s...
Executive/Board ChangesM&A TransactionsRegulatory Filings and Compliance
Avidity Biosciences Receives FTC Clearance for Novartis Merger
Positive
Dec 18, 2025
On October 25, 2025, Avidity Biosciences entered into a merger agreement under which a Novartis wholly owned subsidiary will merge with Avidity, leaving Avidity as an indirect wholly owned subsidiary of Novartis, and on December 14, 2025 the board...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.